Moleculin Announces World Health Organization Approval of “Naxtarubicin” As International Non-Proprietary Name for Annamycin

Moleculin Biotech, Inc. announced that the International Nonproprietary Names Expert Committee of the World Health Organization approved “naxtarubicin” for the non-proprietary name of the company’s next-generation anthracycline in development for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.